Biovica, active in cancer diagnostics, today announces that DiviTum®TKa results from an analysis of samples from the large SWOG S0226 study have been published in the highly ranked peer-reviewed scientific journal Clinical Cancer Research, published by the American Association for Cancer Research (AACR). The strong results support using DiviTum®TKa as a tool to monitor disease progression with endocrine therapy in women with hormone receptor positive metastatic breast cancer.
Biovica, active in cancer diagnostics, today announces that DiviTumTKa results from the large BioItaLEE study will be presented as a poster during the European Society for Medical Oncology (ESMO) meeting 16 to 21 September 2021. The results strengthen the potential of DiviTum®TKa as a treatment monitoring devise for CDK4/6 inhibitor treatments.
Biovica, active in cancer diagnostics, today announced that the company’s expected timeline for its updated 510(k)-application to the US Food and Drug Administration (FDA) has been prolonged due to delay in response from FDA.
The annual general meeting of Biovica International AB (“Biovica” or the “Company”) was held today on 31 August 2021 and the following resolutions were passed by the meeting.
SEK 000s Q1 21/22 Q1 20/21 May-April 20/21 Net sales 381 340 2,077 Operating profit (loss) -12,238 -8,665 -40,181 Profit (loss) for the period -12,225 -8,374 -39,482 Earnings per share, after dilution -0.43 -0.36 -1.39 Significant events during the first quarter The PROMIX breast cancer study at Karolinska University Hospital has been published in the […]
Biovica, active in cancer diagnostics, today announced that a pre-recorded presentation with CEO Anders Rylander has been published.
Biovica, active in cancer diagnostics, today announced that Warren Cresswell has been appointed President Americas and will be part of the management team.
The shareholders of Biovica International AB, reg. no. 556774-6150, (the “Company”) are hereby invited to the annual general meeting on Tuesday 31 August 2021.
Annual report for the financial year 2020/2021 for Biovica International AB is published today on our website
Preparations for the launch of DiviTum®TKa